March 12, 2020 / 12:20 PM / 20 days ago

BRIEF-Agenus Receives Fast Track Designation For Balstilimab & Zalifrelimab In Advanced Cervical Cancer

March 12 (Reuters) - Agenus Inc:

* AGENUS RECEIVES FAST TRACK DESIGNATION FOR BALSTILIMAB & ZALIFRELIMAB IN ADVANCED CERVICAL CANCER

* AGENUS INC - EXPECTS TO FILE 2 BLAS THIS YEAR FOR ACCELERATED APPROVAL OF COMBINATION OF BALSTILIMAB AND ZALIFRELIMAB AND BALSTILIMAB MONOTHERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below